
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is a potentially exciting opportunity for investors seeking exposure to the rapidly growing oncology market with an innovative precision medicine approach. With multiple clinical-stage assets including darovasertib, IDE397, IDE849, IDE275, IDE161, and IDE705, IDEAYA has a diverse pipeline with the potential for multiple future revenue streams. The recent positive topline results from the pivotal Ph. 2/3 OptimUM-02 study for darovasertib suggest a significant potential for off-label use in HLA-A*02:01-positive metastatic uveal melanoma (mUM) patients, representing a $150M additional TAM opportunity.
Bears say
IDEAYA Biosciences is an oncology-focused precision medicine company with a diverse pipeline of clinical and preclinical product candidates. While its approach of integrating small molecule drug discovery with biomarker identification is promising, the company is not yet generating any revenue from its products. Additionally, the company's current valuation appears overinflated, with a DCF analysis estimating a value of only $54 per share, indicating potential downside risk for investors.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares